Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 May;122(11):1724-1725.
doi: 10.1038/s41416-020-0819-5. Epub 2020 Mar 31.

Comment on: "Exploring the best treatment options for BRAF-mutant metastatic colon cancer"

Gérard Milano  1 , Jocelyn Gal  2
Affiliations
Comment

Comment on: "Exploring the best treatment options for BRAF-mutant metastatic colon cancer"

Gérard Milano et al. Br J Cancer. 2020 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
BRAF - mutated metastatic CRC: molecular bases for an optimal combination BRAFi - MEKi - cetuximab - bevacizumab - CPI.
See this image and copyright information in PMC

Comment on

References

    1. Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A. Exploring the best treatment options for BRAF-mutant metastatic colon cancer. Br. J. Cancer. 2019;121:434–42. doi: 10.1038/s41416-019-0526-2. - DOI - PMC - PubMed
    1. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427–430. doi: 10.1038/nature08902. - DOI - PMC - PubMed
    1. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464:431–435. doi: 10.1038/nature08833. - DOI - PubMed
    1. Zhang C, Spevak W, Zhang Y, Burton EA, Ma Y, Habets G, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015;526:583–586. doi: 10.1038/nature14982. - DOI - PubMed
    1. Adelmann CH, Ching G, Du L, Saporito RC, Bansal V, Pence LJ, et al. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget. 2016;7:30453–30460. doi: 10.18632/oncotarget.8351. - DOI - PMC - PubMed

MeSH terms

Substances